Comment on: Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis
Rheumatology (Oxford)
.
2023 Dec 1;62(12):e349-e350.
doi: 10.1093/rheumatology/kead312.
Authors
Onofre Moran-Mendoza
1
2
,
Ahmad Al-Jarallah
1
2
,
Salem Alqahtani
1
2
,
Carla Paredes
2
Affiliations
1
Division of Respirology and Sleep Medicine, Queen's University, Kingston, ON, Canada.
2
Kingston Health Sciences Center, Kingston, ON, Canada.
PMID:
37369016
DOI:
10.1093/rheumatology/kead312
No abstract available
MeSH terms
Humans
Immunosuppressive Agents
Lung
Lung Diseases, Interstitial* / drug therapy
Lung Diseases, Interstitial* / etiology
Scleroderma, Systemic* / complications
Scleroderma, Systemic* / drug therapy
Substances
Immunosuppressive Agents